Adherium’s Hailie® Smartinhaler® technology and cloud-based data collection solution provide a clinically proven medication adherence solution, with extensive inhaled medication coverage. ​

View Our Technology
 

The accelerated adoption of telehealth and remote patient monitoring, together with favourable reimbursement in the US, plays directly to Adherium’s strengths.

See the Adherium Opportunity
 

Global treatment guidelines recommend the use of electronic monitoring tools in the assessment of the adherence of patients with difficult-to-treat or severe asthma, prior to changing their medication.

Read the Non-Adherence Epidemic
 

Since 2022, an exciting new generation of sensors which enable the capture of physiological parameters.

View Our Technology

Adherium Limited is an international Respiratory eHealth company focused on patient adherence, remote monitoring and data management solutions for patients, physicians, payers, and providers. Adherium’s Hailie® Smartinhaler® technology and secure cloud data platform enables physicians and payers to optimally manage patient adherence for difficult-to-treat and severe asthma and COPD, and reduce direct and indirect healthcare costs.

Read More

news

  • Four in five Aussie asthma sufferers to breathe easier under new technology
  • $2.6 million Capital Raise to Progress Roll-Out of Hailie® Smartinhaler® Platform in the US
  • Sunrise on Ch 7

Numbers

SHARE PRICE

Updated: AEST

AUD

Need

Medication non-adherence in respiratory patients leads to a preventable healthcare cost estimated at $34 billion in the US alone​.

Now

COVID-19 has accelerated adoption of remote patient monitoring, with favourable reimbursement in the US​.

This website uses cookies that have security, network management and accessibility functions. You can disable them in your browser settings, but this may affect your experience of the website. Click here to find out more.